Nucana reports fourth quarter and year-end 2024 financial results and provides business update

Remains on track to initiate an expansion study of nuc-7738 in combination with pembrolizumab for patients with pd-1 inhibitor-resistant melanoma in 2025

NCNA Ratings Summary

NCNA Quant Ranking